Author

Lisa Caunt

Observed institution: Clovis Oncology (United States)

OpenAlex ID: A5060460879

First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M).

2014 · Lecia V. Sequist, Jean-Charles Soria, et al. · Journal of Clinical Oncology · 143

Abstract CT158: ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer

2019 · Shannon N. Westin, Rebecca S. Kristeleit, et al. · Cancer Research · 11

Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety.

2025 · Alan Haruo Bryce, Raymond S. McDermott, et al. · Journal of Clinical Oncology · 8

Mp16-07 Rucaparib Vs Docetaxel or Second-generation Androgen Receptor Pathway Inhibitor Therapy for Metastatic Castration-resistant Prostate Cancer Patients With Brca Mutations With or Without Liver Metastases in Triton3

2025 · David Morris, Alan H. Bryce, et al. · The Journal of Urology · 1

Abstract CT158: ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer

2019 · Shannon N. Westin, Rebecca S. Kristeleit, et al. · Clinical Trials

Works count: 5

Citation count: 163

H-index: 3

I10-index: 2